Case Reports
doi: 10.1016/j.cllc.2019.11.011.
Epub 2019 Nov 20.
Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report
Affiliations
- PMID: 31902695
- DOI: 10.1016/j.cllc.2019.11.011
Item in Clipboard
Case Reports
Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report
Clin Lung Cancer.
2020 Mar.
No abstract available
Keywords: Atezolizumab; Immune checkpoint inhibitor rechallenge; Immunotherapy; Lung cancer; Nivolumab.
Similar articles
-
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.Thorac Cancer. 2020 Jul;11(7):1927-1933. doi: 10.1111/1759-7714.13483. Epub 2020 May 18. Thorac Cancer. 2020. PMID: 32421224 Free PMC article.
-
Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.Int J Cancer. 2018 Dec 1;143(11):3038-3040. doi: 10.1002/ijc.31733. Epub 2018 Sep 25. Int J Cancer. 2018. PMID: 29987914 No abstract available.
-
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.Future Oncol. 2019 Jul;15(20):2423-2433. doi: 10.2217/fon-2018-0868. Epub 2019 Jun 25. Future Oncol. 2019. PMID: 31237152
-
Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.Crit Rev Oncol Hematol. 2019 Oct;142:16-25. doi: 10.1016/j.critrevonc.2019.07.004. Epub 2019 Jul 10. Crit Rev Oncol Hematol. 2019. PMID: 31326706
-
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer.Crit Rev Oncol Hematol. 2025 May;209:104683. doi: 10.1016/j.critrevonc.2025.104683. Epub 2025 Feb 28. Crit Rev Oncol Hematol. 2025. PMID: 40024354 Review.
Cited by
-
The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge-A Systematic Review.Cancers (Basel). 2023 Jul 4;15(13):3490. doi: 10.3390/cancers15133490. Cancers (Basel). 2023. PMID: 37444600 Free PMC article. Review.
-
Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review.J Clin Med. 2023 Feb 24;12(5):1833. doi: 10.3390/jcm12051833. J Clin Med. 2023. PMID: 36902620 Free PMC article. Review.
-
Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.Front Immunol. 2021 Nov 26;12:727464. doi: 10.3389/fimmu.2021.727464. eCollection 2021. Front Immunol. 2021. PMID: 34899689 Free PMC article.
-
Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?World J Clin Oncol. 2022 Sep 24;13(9):729-737. doi: 10.5306/wjco.v13.i9.729. World J Clin Oncol. 2022. PMID: 36212599 Free PMC article. Review.
-
Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report.Front Immunol. 2025 Jun 30;16:1618672. doi: 10.3389/fimmu.2025.1618672. eCollection 2025. Front Immunol. 2025. PMID: 40661961 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
